Certara (NASDAQ:CERT) Given “Market Perform” Rating at William Blair

William Blair reiterated their market perform rating on shares of Certara (NASDAQ:CERT) in a report issued on Thursday morning,RTT News reports.

Other equities research analysts have also issued reports about the stock. Robert W. Baird lowered their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday. They set a “buy” rating and a $16.00 price target for the company. Stephens reaffirmed an “overweight” rating and set a $17.00 price objective on shares of Certara in a research note on Thursday. Finally, Barclays lowered their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Certara currently has a consensus rating of “Hold” and an average target price of $15.64.

Certara Price Performance

Shares of Certara stock opened at $12.40 on Thursday. The firm has a market capitalization of $2.00 billion, a PE ratio of -62.00, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The business’s 50-day moving average price is $12.43 and its 200-day moving average price is $11.64.

Institutional Investors Weigh In On Certara

A number of large investors have recently made changes to their positions in the business. Venturi Wealth Management LLC lifted its stake in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Blue Trust Inc. lifted its position in Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after buying an additional 2,076 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Certara in the 4th quarter worth about $47,000. Finally, KBC Group NV increased its stake in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after acquiring an additional 1,584 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.